Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGattaca Regulatory News (GATC)

Share Price Information for Gattaca (GATC)

Share Price is delayed by 15 minutes
Get Live Data
147.50    -1.50 (-1.01%)
Bid:
145.00
Ask:
150.00
Spread: 5.00 (3.448%)
Market Cap: £45.56m
GATC Live PriceLast checked at - London Stock Exchange

Intraday Gattaca Share Chart

Trading Update

17 Aug 2021 07:00

RNS Number : 8021I
Gattaca PLC
17 August 2021
 

17 August 2021

 

Gattaca plc

("Gattaca", "the Group" or "the Company")

 

Trading Update for 12 months ended 31 July 2021

Performance ahead of expectations

 

 

Gattaca plc (LSE-AIM: GATC), the UK's leading specialist Engineering and Technology staffing business, today provides the following trading update for the 12 months ended 31 July 2021.

 

Following our trading update announcement on 21 May 2021, we expect continuing underlying PBT1 and adjusted net cash (excluding IFRS16 lease liabilities) to be above market expectations for FY 2021.

 

H2 2021 continuing Net Fee Income ("NFI") was 7% higher than H1 2021, with the full year NFI at £42.5m (FY 2020: £52.8m), reflecting the market impact of the COVID-19 pandemic over the entire reporting period.

 

We continue to add sales and delivery resource across the business, increasing front line headcount by 13% since January whilst tightly managing the overall cost base.

 

Consequently, subject to final adjustments and audit, we expect our continuing underlying PBT for the full year to be in excess of £3m (market consensus £2.7m).

 

Adjusted Net Cash (excluding IFRS16 lease liabilities) is expected to be £20m2 (31 July 2020: £27m) largely driven by repayment of deferred VAT (£4.7m)

 

All of our businesses successfully transferred to our global technology platform in Q4 enabling the business to have a consistent view of activity and performance across all of our operating units. 

We have seen increased activity from our "RPO" (Permanent Recruitment Process Outsourcing solutions) clients as the market recovery has been led by permanent recruitment both in contingent and solutions products. There is further improvement to come on the contract front including in our core infrastructure unit, which will benefit from strong demand driven by major initiatives such as UK Fibre investment, HS2 and Offshore 2025, which we are seeing already positively impacting hiring. Our defence business continues to perform strongly. We also anticipate continuing high demand for technology skills as the pace of digitisation continues to accelerate.

 

We have determined that our sales operations in Mexico and South Africa are sub-scale and we exited both at the end of July and these businesses will be treated as discontinued in our FY 2021 results.

 

In light of the improved performance and assuming a continuation of the current positive trends, the Board anticipates the recommendation of a modest dividend when the full year results are announced.

 

The Group expects to announce its full year results for the 12 months to 31 July 2021 on Thursday 4 November 2021.

 

 

 

Kevin Freeguard, Chief Executive Officer said:

 

"Following our upgrade in May, I am pleased that our profit results will again be ahead of expectations. Whilst the pandemic continues to impact activity across our markets, it is clear that we have now entered the next phase of recovery. Our new global technology platform will increase our ability to collaborate and drive performance across the business. At the same time, our continued investment in sales and delivery resources will enable us to capitalise on the continuing opportunities as our markets, including Infrastructure and Defence, emerge from the pandemic."

 

1 Continuing underlying results exclude the NFI and (losses) / profits before taxation of discontinued operations. The combined NFI of Mexico and South Africa in the year was £1.0m and losses before tax were £(0.2)m (2020: NFI £1.5m and profit before tax £0.2m

2 VAT deferrals at 31 July 2021 were £5.6m (31 July 2020: £10.3m)

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

 

For further information please contact:

Gattaca plc

+44 (0) 1489 898989

Kevin Freeguard, Chief Executive Officer

Salar Farzad, Chief Financial Officer

 

 

Liberum Capital Limited (Nomad and Broker)

+44 (0) 20 3100 2000

Lauren Kettle

Robert Morton

Euan Brown

 

 

 

Citigate Dewe Rogerson

+44 (0) 20 7638 9571

Jos Bieneman

Elizabeth Kittle

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTEQLFFFVLFBBX
Date   Source Headline
14th May 20267:00 amRNSTrading Update
1st Apr 20267:00 amRNSBLOCK LISTING SIX MONTHLY RETURN
24th Mar 20267:00 amRNSInterim Results
11th Mar 20267:00 amRNSNotice of Results and Investor Presentations
11th Mar 20267:00 amRNSNotice of Results and Investor Presentations
11th Feb 20267:00 amRNSTrading Update
31st Dec 20257:00 amRNSDirector/PDMR dealing
31st Dec 20257:00 amRNSDirector/PDMR dealing
19th Dec 20253:29 pmRNSGrant of Options and Director/PDMR dealing
19th Dec 20253:29 pmRNSGrant of Options and Director/PDMR dealing
16th Dec 202512:19 pmRNSExercise of Options and Director/PDMR Shareholding
11th Dec 20259:05 amRNSResults of Annual General Meeting
10th Nov 20257:00 amRNSAvailability of Report & Accounts and AGM Notice
23rd Oct 20257:00 amRNSFinal results for the year ended 31 July 2025
15th Oct 20257:00 amRNS-RInvestor Presentation via Investor Meet Company
13th Oct 20252:59 pmRNSBlock Listing Six Monthly return
8th Oct 20257:00 amRNSNotice of Results
5th Aug 20257:00 amRNSTrading update and Acquisition
22nd Jul 20257:00 amRNSEBT Share Purchase Programme
21st Jul 20256:22 pmRNSExercise of Options and Director/PDMR Shareholding
2nd Apr 20252:21 pmRNSCORRECTION – Interim Results
2nd Apr 20257:00 amRNSInterim Results
1st Apr 20257:00 amRNSBLOCK LISTING SIX MONTHLY RETURN
13th Feb 20257:00 amRNSTrading Update
27th Jan 20254:51 pmRNSFurther re EBT Share Purchase Programme
11th Dec 20243:59 pmRNSDirector/PDMR Shareholding
11th Dec 20242:25 pmRNSResult of AGM
11th Nov 20242:29 pmRNSAvailability of Report & Accounts and AGM Notice
30th Oct 20247:00 amRNSEBT Share Purchase Programme
24th Oct 20247:00 amRNSFinal results for the year ended 31 July 2024
1st Oct 20247:00 amRNSBlock listing Six Monthly Return
15th Aug 20247:00 amRNSTrading Update for the year ended 31 July 2024
16th Jul 202410:36 amRNSDirector/PDMR Share Purchase
11th Jul 202411:13 amRNSExercise of Options
1st Jul 20247:00 amRNSNominated Adviser and Broker
16th Apr 20247:00 amRNSInterim Results
2nd Apr 20247:00 amRNSBlock listing six monthly return
15th Feb 20247:00 amRNSTrading Update
25th Jan 20247:00 amRNSExercise of Options
6th Dec 20235:07 pmRNSDirector/PDMR Shareholding
6th Dec 20234:51 pmRNSResults of Annual General Meeting
28th Nov 20237:00 amRNSTransaction in Own Shares
27th Nov 20237:00 amRNSTransaction in Own Shares
24th Nov 20237:00 amRNSTransaction in Own Shares
22nd Nov 20237:00 amRNSTransaction in Own Shares
21st Nov 20237:00 amRNSTransaction in Own Shares
20th Nov 20237:00 amRNSTransaction in Own Shares
17th Nov 20237:00 amRNSTransaction in Own Shares
15th Nov 20237:00 amRNSTransaction in Own Shares
14th Nov 20237:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.